New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Al
Go back to New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at The Al| BIOGEN IDEC Inc. (NASDAQ: BIIB) | Delayed: 200.58 +0.87 (0.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $199.71 | 52 Week High | $333.65 | |||
| Open | $198.88 | 52 Week Low | $223.02 | |||
| Day High | $201.00 | P/E | 25.68 | |||
| Day Low | $198.42 | EPS | $7.81 | |||
| Volume | 128,392 | |||||
